Researchers at the Colorado Blood Cancer Institute have devised a successful, long-term treatment for relapsing/remitting multiple sclerosis (RRMS). The treatment approach seeks to ‘reboot’ the patient’s immune system by effectively erasing it and then rebooting it using the patient’s own [autologous] stem cells. The treatment resulted in a disease reversal rate of 86% and halted progression rate of 91% in patients participating in the study. Study patients underwent immunosuppressive therapy for up to four weeks, after which autologous stem cells were re-infused to restore a healthy immune systems. Patients were then followed for up to five years.
In multiple sclerosis, which affects 2.5 million people worldwide, the patient’s own immune system attacks myelin—a vital component of axons aiding in both protection and signal transduction of nerve impulses. Restoring study subjects’ immune systems protected, and in some cases restored, myelin - increasing function, and decreasing disability. “At 3 years, HDIT/HCT [high-dose immunosuppressive therapy/autologous hematopoietic cell transplant] without maintenance therapy was effective for inducing sustained remission of active RRMS and was associated with improvements in neurologic function. Treatment was associated with few serious early complications or unexpected adverse events,” the study authors wrote in a recent issue of JAMA Neurology.
This aggressive and effective therapy could revolutionize treatment for multiple sclerosis, transforming a chronic, progressive condition to an illness that can be cured. The Colorado Blood Cancer Institute’s research is an example of the potential for stem cell regenerative medical therapies to effectively treat seemingly intractable and incurable conditions. To learn more about stem cells and how to insure immediate access to emerging personalized regenerative treatments by banking your own valuable dental pulp stem cells, please visit StemSave or call 877-783-6728 (877- StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.